Maze Therapeutics, Inc. (MAZE) has 16 SEC Form 4 insider filings on record in the last 90 days. No insider purchases were filed — 8 sales totalling $4.1M. Most recent filing: Sept. 8, 2026.
| Date | Insider | Value | Shares | Stake | Pre-planned | Links |
|---|---|---|---|---|---|---|
| Sept. 8, 2026 filed Sept. 4, 2026 | Bernstein Harold President, R&D & CMO | −$254,502 | 9,705 | −100% | Yes | |
|
|
||||||
| Sept. 4, 2026 filed Sept. 2, 2026 | Courtney Phillips GC and Corp. Secretary | −$104,766 | 3,993 | −36% | No | |
|
|
||||||
| Sept. 4, 2026 filed Sept. 2, 2026 | Dandekar Atul CSBO | −$168,811 | 6,434 | −17% | No | |
|
|
||||||
| Sept. 4, 2026 filed Sept. 2, 2026 | Coloma Jason V Chief Executive Officer | −$593,955 | 22,638 | −45% | No | |
|
|
||||||
| Sept. 4, 2026 filed Sept. 2, 2026 | Bernstein Harold President, R&D & CMO | −$270,111 | 10,295 | −51% | No | |
|
|
||||||
Showing the 5 most recent of 16 filings in the last 90 days.
Form 4 is the filing company officers, directors and 10% shareholders must submit to the SEC within two business days of trading their own company's stock. Open-market purchases generally carry more signal than sales, which are often scheduled in advance. More on how this works.
Real-time Telegram alerts the moment a Form 4 is filed. Filings shown here are delayed by 72 hours.
Start free